|
Match
|
Document |
Document Title |
|
|
5008196 |
Stimulation of endothelial cell growth
A method of stimulating endothelial cell growth is provided which comprises subjecting said cells to a growth stimulating amount of a highly purified vascular permeability factor having the...
|
|
|
5008242 |
Treatment of inflammation using 1-antichymotrypsin
A method for the prophylaxis or direct treatment of inflammation in a mammal or fowl which comprises administering an effective amount of alpha 1-antichymotrypsin, its salts or derivatives.
|
|
|
5004604 |
Immuno-suppressive material and process for preparing same
An immuno-suppressor is described in the form of an immuno-suppressor serum and/or an IS-IgG extracted from this serum, produced by immunisation of an animal with antibody-covered cells; also...
|
|
|
5004802 |
100KDa protein from blood which binds to and inhibits the activity of plasminogen activators
A protein called PA binding protein has been isolated which binds specifically and reversibly to tissue plasminogen activator. The protein is characterized by a molecular mass of about 100,000...
|
|
|
4997915 |
Purification of pertussis toxins
Lymphocytosis promoting factor (LPF) and filamentous hemaglutinin (FHA) are isolated from the growth medium of the Bordatella pertussis organism and purified by selecting adsorbing the LPF and FHA...
|
|
|
4996296 |
Cromolyn binding protein in highly purifed form, and methods for the isolation thereof
Substantially pure cromolyn binding protein is prepared by means of affinity chromatography of cromolyn derivatives bound to insoluble matrices. Aminocromolyn is prepared by a six-step synthesis...
|
|
|
4996297 |
Recombinantly expressed rabbit zona pellucida polypeptides
The invention relates to antigenic preparations useful for inducing the production of antibodies in an individual which will bind to epitopes on zona pellucida. Also disclosed are immunogenic...
|
|
|
4980456 |
Recombinant factor VIIIC derived fragments
New fragments of the Factor VIII procoagulant protein (Factor VIIIC) are disclosed. These fragments have an Mr value of 88,000 d or 49,000 d or extend from amino acid residues 1974 to 2332 or 2052...
|
|
|
4975246 |
High temperature, short time heating system and method of heating heat-sensitive material
A high temperature, short time heating system and method for the pasteurization and/or sterilization of heat-sensitive material to destroy substantially selected pathogenic microorganisms without...
|
|
|
4973668 |
Variants of alpha 1-antitrypsin which are useful, in particular, as kallikrein inhibitors
The invention relates to the variant of human alpha 1 -antitrypsin of formula: (Ala 357 , Arg 358 ) alpha 1 -AT. This compound is useful as a kallikrein inhibitor.
|
|
|
4971792 |
Monoclonal antibodies against glycolipid antigens
The present invention is directed to in vitro and in vivo immunodiagnosis and immunotherapy using monoclonal antibodies reactive with difucosyl blood group antigens Y-6 and B-7-2.
|
|
|
4970152 |
Reagents for determining peptidoglycan and β-1,3-glucan
A reagent comprising a fraction obtained from plasma of an insect such as silkworm larvae and capable of reacting specifically with β-1,3-glucan or peptidoglycan can be used for determining...
|
|
|
RE33405 |
Purified human prostate antigen
A prostate antigen distinct from prostatic acid phosphatase has been detected in normal, benign hypertrophic and malignant prostatic tissues, but not in other human tissues. The prostate antigen...
|
|
|
4965251 |
Pulse treatment of hemoglobinopathies with erythropoietin
A method of treating a hemoglobinopathic condition such as sickle cell anemia, by pulse treatment with erythropoietin. In one embodiment, each of one or more treatment regimens includes a first...
|
|
|
4963657 |
Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
Novel cell lines produce monoclonal antibody to the light chain region of human factor XII. Three such cell lines, ATCC #HB-9703 through ATCC #HB-9704, are formed by fusing SP2/0-Ag14 myeloma cells...
|
|
|
4957903 |
Pharmaceutical and clinical compositions of desAA fibrin monomers and the tetrapeptide gly-pro-arg-pro
The invention relates to a fully solubilizable fibrin based composition, which is characterized by the combination that the fibrin is desAA-fibrin or desAA-fibrin from which the C-terminal portions...
|
|
|
4946648 |
Method of sterilizing plasma or plasma fractions
A method of sterilizing plasma or plasma fractions, including fractions that contain the blood-coagulating Factor VIII by treatment with β-propiolactone or ultraviolet radiation. Treatment with...
|
|
|
4946774 |
Process for detecting cancer and for monitoring the effectiveness of cancer therapy
A process for detecting cancer in a human patient is provided wherein a blood serum is recovered from the patient and is reacted with a monoclonal antibody comprising anti-haptoglobin variant under...
|
|
|
4945054 |
Process for the separation and purification of proteases and antiproteases of blood clotting, as well as of the protease/antiprotease complex
The present invention relates to a process for separating and purifying proteases and antiproteases. This process is characterized in that there are placed in contact an insoluble cross-linked...
|
|
|
4939176 |
Viral inactivation process
Lipid-enveloped viruses present in purified biologically active protein products obtained from blood or cell culture systems can be inactivated by contacting the products with caprylic acid at a...
|
|
|
4937071 |
Method for augmenting immune response
A method for enhancing the ability for humoral immune response in a mammal comprising: exposing lymphocytes histocompatible with the lymphocytes of said mammal to the presence of...
|
|
|
4931548 |
Heterodimer form of transforming growth factor-beta
A polypeptide transforming growth factor found in porcine platelets, having activity in the TGF-β assay and a molecular weight of about 25 kDa. The factor is a heterodimer, one chain of which has...
|
|
|
4927916 |
Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides
Peptides comprising fibrin-specific epitopic sequences are used to prepare hybridoma cell lines producing antifibrin-specific monoclonal antibodies substantially devoid of...
|
|
|
4917804 |
Method and vessel for separation of cryoglobin
A set for the isolation of cryoprecipitate includes a hollow vessel with a closed first end, a second end and a longitudinal axis, and a nipple extending from and closing the second end, said...
|
|
|
4915847 |
Cryoglobulin separation
A set for the isolation of cryoprecipitate includes a hollow vessel with first and second ends and a tapered body extending to a narrow sump closing the second end, said sump enclosing a volume of...
|
|
|
4915945 |
Process for the preparation of the C1 inactivator
The invention relates to a process for the preparation of C1 inactivator, which, if appropriate, is hepatitis-free and, if appropriate, can be lyophilized, and its use as a medicament.
|
|
|
4906734 |
Human conglutinin
Human conglutinin, polyclonal, and monoclonal antibodies raised against human conglutinin, and their uses in therapy and diagnosis are described. Human conglutinin was obtained from human plasma by...
|
|
|
4900447 |
Method for determination of mucoprotein vector
Method for determination of mucoprotein vector from blood serum and its eluates through separation of the blood serum mucoproteins by means of gel ion-exchanger chromatography into at least two...
|
|
|
4900720 |
Replacement of human plasma using sterile solution of human plasma proteins excluding blood coagulation factors
To maintain an almost unchanged plasma-protein profile in a patient subsequent to plasma exchange, the plasma-exchange medium contains the most essential human serum proteins, except for the...
|
|
|
4891319 |
Protection of proteins and the like
Sensitive proteins and other macromolecules, such as enzymes, antibodies, antigens, serum complement, fluorescent proteins, vaccine components, polysaccharides such as agarose etc, can be preserved...
|
|
|
4889919 |
Biologically active PDGF derived A-chain homodimers
Dimeric proteins having substantially the same biological activity as PDGF are disclosed. More specifically, the protein may have two substantially identical polypeptide chains, each of the chains...
|
|
|
4886780 |
Conjugates of apotransferrin proteins with anti-tumor agents
Conjugates of transferrin or ceruloplasmin with anti-tumor agents. Such conjugates are useful in the treatment of tumors. Suitable anti-tumor agents include adriamycin, daunomycin, methotrexate,...
|
|
|
4883784 |
Human complement factors and their therapeutic use
The administration of Factor I and/or Factor H to a mammal has been found to alleviate or prevent such autoimmune diseases as systemic lupus erythematosus, rheumatoid arthritis and glomerulonephritis.
|
|
|
4882423 |
Substance-conjugated complement component C1q
A substance-conjugated complement component Clq is provided. A substance such as signal emitting substances or cell function regulating substances is conjugated via a sulfur atom to at least one...
|
|
|
4879272 |
Method and composition for preventing the adsorption of a medicine
A method of preventing erythropoietin in an aqueous solution from being adsorbed on the inner surface of the wall of a container by incorporating in the aqueous solution one or more additives, and...
|
|
|
4877608 |
Pharmaceutical plasma protein formulations in low ionic strength media
Stable factor VIII and other plasma protein formulations are provided in low ionic strength media which comprises: sodium chloride, potassium chloride or mixtures thereof; lysine hydrochloride; and...
|
|
|
4874746 |
Wound headling composition of TGF-alpha and PDGF
Healing an external wound or regenerating bone of a mammal by administering to the mammal a composition containing purified platelet-derived growth factor and purified transforming growth factor...
|
|
|
4869826 |
Cellular adsorbents for removal of viral contaminants from blood and complex protein solutions
Cellular adsorbents for removing viral contaminants from whole blood and protein solutions are prepared by immobilizing and stabilizing cells or portions thereof cellular receptors for the target...
|
|
|
4863897 |
Protein and mineral water-containing cosmetic compositions
This invention relates to cosmetic, health- and body-preserving compositions of high biological value, optimizing the biological processes occurring in the skin cells and providing the most...
|
|
|
4859766 |
Purified appetite-regulating substances of biological orgin, their antibodies, immunocomplexes of the appetite--regulating substances formed with the antibodies and processes for preparing same
The selective appetite-regulating substances satietin and satietin-D had up to the present been prepared from human or animal blood serum or plasma by ultrafiltration, gel chromatography, treatment...
|
|
|
4857317 |
Process for the extraction and purification of proteins from culture media producing them
The process is applicable to the supernatant of engineered yeast cells disrupted in the presence of a non-ionic detergent; it comprises the precipitation of contaminants by polyethylene glycol and...
|
|
|
4853220 |
Protein isolated from blood, process for preparing said protein, aantibodies against said new protein, and pharmaceutical compositions containing said protein or said antibodies
The invention relates to Tetranectin, a new protein isolated from blood. Its structure comprises four polypeptide chains having the formula shown in the attached drawing. Tetranectin plays a role...
|
|
|
4844895 |
Composition containing a peptide fragment of platelet factor four and method for restoring suppressed immune responses
Compositions and methods for modulating immune responses in mammals comprising immunomodulating-effective amounts of PF4 or a biologically active peptide fragment of platelet factor 4 are disclosed...
|
|
|
4841026 |
Virally inactivated, non-toxic, human transferrin preparation
Method and composition for providing a non-toxic, sterile, virally inactivated human transferrin preparation for use in cell culture systems. The method comprises saturation of the transferrin with...
|
|
|
4841023 |
Inactivation of viruses in labile protein-containing compositions using fatty acids
There is disclosed a process for rendering a labile protein-containing composition, substantially free of lipid-containing viruses without incurring substantial protein denaturation comprising...
|
|
|
4835260 |
Erythropoietin composition
A new improved glycoprotein having erythropoietin-type activity is disclosed. The substrate is characterized by amino acid sequence substantially identical to the amino acid sequence of native...
|
|
|
4833165 |
Method of inactivating HTLV-III virus in blood
HTLV-III virus in blood or blood components is inactivated by treatment with about 0.1-5% of phenol, formaldehyde, or mixtures thereof, at a temperature of about 2°-40° C. for at least about 5...
|
|
|
4833074 |
Purified human granylocyte L1 proteins methods for their preparation, monospecific antibodies and test kits
The invention concerns the two pure human granulocyte L1 proteins of pI 6.3 and pI 6.5, and mixtures thereof, methods for their isolation and purification, their use as marker proteins and...
|
|
|
4831119 |
Preparation for the treatment of hemophilia A inhibitor patients and a process for producing such a preparation
A preparation for the treatment of hemophilia A inhibitor patients contains a protein or peptide having a specific Factor VIII:CAg activity of at least 0.5, preferably at least 1 VIII:CAg unit per...
|
|
|
4831118 |
Flouroplastic immunoaffinity columns for purification of blood proteins
The present invention is a protein purification column comprising an organic substrate matrix having low reactivity to proteins, said matrix being capable of maintaining monoclonal antibodies...
|